46. Malignant rheumatoid arthritis Clinical trials / Disease details
Clinical trials : 4,356 / Drugs : 2,567 - (DrugBank : 415) / Drug target genes : 192 - Drug target pathways : 228
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04779892 (ClinicalTrials.gov) | February 1, 2020 | 26/2/2021 | The Study of Infliximab (CMAB008 and Remicade) in Healthy Subjects to Compare the PK and Safety | The Study of Infliximab (CMAB008 and Remicade) in Healthy Subjects to Compare the PK and Safety | Rheumatoid Arthritis | Drug: Infliximab | Taizhou Mabtech Pharmaceutical Co.,Ltd | NULL | Completed | 18 Years | 45 Years | Male | 90 | Phase 1 | China |
| 2 | NCT03478111 (ClinicalTrials.gov) | March 30, 2018 | 16/3/2018 | CMAB008 With MTX Therapy in Adult Patients With Moderately to Severely Active Rheumatoid Arthritis | A Randomized, Double-blind, Methotrexate (MTX) Based, Parallel-group, Multicenter Phase III Study to Evaluate Efficacy and Safety of CMAB008 in Adult Patients With Moderately to Severely Active Rheumatoid Arthritis, Compared to Remicade | Rheumatoid Arthritis | Drug: CMAB008;Drug: MTX;Drug: Remicade | Shanghai Biomabs Pharmaceutical Co., Ltd. | NULL | Completed | 18 Years | N/A | All | 390 | Phase 3 | China |